EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Bevacizumab and thrombosis risk in cancer patients with COVID-19: A national retrospective cohort study (TIC-TAC)

Adrien Migeon, Emeline Laurent, Romain Chautard, Hugo Desmars, Pascal Vigny, Anne-Isabelle Lecuyer, Leslie Grammatico-Guillon, Thierry Lecomte

PLOS One · 19.11.2026 · 21 (11) · e0362952

DOI: 10.1371/journal.pone.0362952 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift PLOS One, online erschienen am 19.11.2026. Verfasst von Adrien Migeon und 7 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LEO Pharma.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer patients treated with bevacizumab are at increased risk of thromboembolic events. COVID-19 is also associated with thromboembolism, but its impact on thromboembolic risk in cancer patients receiving bevacizumab remains unclear. The TIC-TAC study aimed to assess whether COVID-19 diagnosis is associated with an increased risk of venous thromboembolic events (VTE) within 30 days or arterial (ATE) thromboembolic events within 90 days in this population.

Methods

A retrospective nationwide cohort study was conducted using the French national health data system. Cancer patients treated with bevacizumab between January 2019 and December 2021 were included. Bevacizumab exposures were used as statistical unit, and defined to 5 half-lives (100 days) after its administration. COVID-19 diagnosis was defined by ICD-10 codes or positive virological tests. The primary outcome was the occurrence of VTE or ATE during hospitalization. Cox models with time-dependent exposure and Fine and Gray competing-risk models were used to estimate hazard ratios (HR) and subdistribution hazard ratios (SHR), with death considered as a competing risk.

Results

Among 58,855 patients (median age 67 years, 79.9% with metastatic disease), 5,589 VTE and 1,926 ATE were recorded over 46,750 and 46,915 person-years, respectively. COVID-19 diagnosis was associated with a higher risk of VTE within 30 days after diagnosis in crude (HR 1.89, 95% CI 1.55–2.29) and adjusted Cox models (aHR 1.99 [1.64–2.43]), as well as in the Fine and Gray model (aSHR 1.70 [1.40–2.07]). However, the unadjusted absolute risk increase was modest: one additional VTE per 64.6 person-months of COVID-19 exposure. A significant interaction between COVID-19 diagnosis and anticoagulant therapy was observed in the VTE Cox model (p = 0.007), but not in the Fine and Gray model. No significant association was found between COVID-19 diagnosis and ATE risk.

Conclusion

The study showed that 30 days period after a COVID-19 diagnosis could be associated with an increased risk of VTE in cancer patients treated with bevacizumab. However, the absolute risk difference, although unadjusted and therefore uncertain, appeared modest. Causality cannot be established in this retrospective design. No significant association was observed for ATE.

Förderung

  • LEO Pharma

Zitieren

APA

Migeon, A., Laurent, E., Chautard, R., Desmars, H., Vigny, P., Lecuyer, A., Grammatico-Guillon, L., & Lecomte, T. (2026). Bevacizumab and thrombosis risk in cancer patients with COVID-19: A national retrospective cohort study (TIC-TAC). PLOS One, 21(11), e0362952. https://doi.org/10.1371/journal.pone.0362952

Vancouver

Migeon A, Laurent E, Chautard R, Desmars H, Vigny P, Lecuyer A, et al. Bevacizumab and thrombosis risk in cancer patients with COVID-19: A national retrospective cohort study (TIC-TAC). PLOS One. 2026;21(11):e0362952. doi:10.1371/journal.pone.0362952

BibTeX
@article{Migeon2026,
  author = {Migeon, Adrien and Laurent, Emeline and Chautard, Romain and Desmars, Hugo and Vigny, Pascal and Lecuyer, Anne-Isabelle and Grammatico-Guillon, Leslie and Lecomte, Thierry},
  title = {Bevacizumab and thrombosis risk in cancer patients with COVID-19: A national retrospective cohort study (TIC-TAC)},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {11},
  pages = {e0362952},
  doi = {10.1371/journal.pone.0362952}
}
Kostenlos starten →